Drug intelligence / Profile preview

Psyllium-derived medium-molecular-weight arabinoxylan

Development stage: Preclinical
Administration: Oral

Overview

Psyllium-derived medium-molecular-weight arabinoxylan (MMW-AX) is a polysaccharide derived from psyllium. It is being investigated for its ameliorative effects on Type 2 Diabetes Mellitus (T2DM). MMW-AX works by modulating the gut microbiota, improving microbial diversity, and influencing short-chain fatty acid (SCFA) metabolism. This modulation helps to alleviate glucose and lipid metabolism disorders and liver damage associated with T2DM.

Beyond the preview

Go deeper on Psyllium-derived medium-molecular-weight arabinoxylan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Psyllium-derived medium-molecular-weight arabinoxylan.

Explore the full profile